FDA Accepts Supplemental Application for OPDUALAG by Bristol Myers Squibb
The FDA has accepted a supplemental application for OPDUALAG, a combination of nivolumab and relatlimab-rmbw.
Asset / Drug
Drug and asset intelligence for OPDUALAG with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Combination Therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.